Integrating emerging AL therapies into real‑world MDT decisions

From touchPODCAST · 15:22

Show by touchpodcast

Listen to our expert faculty discuss multidisciplinary treatment decisions for amyloid light-chain amyloidosis (AL), including cardiac and renal care, treatment tolerability and frailty. They also explore emerging fibril-directed therapies and their potential role alongside plasma-cell–directed treatment, informed by clinical evidence and local approval. The multidisciplinary team: Hematologist – Dr. Yawara Kawano, Kumamoto University Hospital, Kumamoto City, Japan Cardiologist – Dr. Christian Nitsche, Medical University of Vienna, Vienna, Austria Amyloidosis specialist with a renal focus – Dr. Paolo Milani, University of Pavia, Pavia, Italy Amyloidosis MDT nurse/coordinator – Ms. Christine Chiti, Royal Free London NHS Foundation Trust, London, UK This touchPODCAST is for healthcare professionals outside of the UK. This activity is supported by an independent medical education grant from Alexion Pharma GmbH. Jointly provided by Partners for Advancing Clinical Education and touchIME. touchIME is an EBAC® accredited provider. For further information, please visit our websites: touchHEMATOLOGY, touchCARDIO and touchNEPHROLOGY

More episodes of touchPODCAST

More episodes

PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.